Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | EED | O75530 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420024 | 1.00 | CHRNB2 (0.39) | CHRNB2CHRNA4EEDCHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL16823516 | 0.98 | CHRNB2 (0.38) | CHRNB2CHRNA4EEDCHRNB4CHRNA3 | |
| SCHEMBL21667896 | 0.88 | SLC6A1 (0.39) | CHRNB2CHRNA4ALDH1A1HRH3HRH4 | |
| SCHEMBL21667900 | 0.88 | SLC6A1 (0.39) | CHRNB2CHRNA4ALDH1A1HRH3HRH4 | |
| SCHEMBL12395690 | 0.88 | SLC6A1 (0.39) | CHRNB2CHRNA4ALDH1A1HRH3HRH4 | |
| SCHEMBL7422519 | 0.81 | HRH3 (0.39) | CHRNB2CHRNA4EEDCHRNB4CHRNA3 | |
| SCHEMBL7422517 | 0.81 | HRH3 (0.39) | CHRNB2CHRNA4EEDCHRNB4CHRNA3 | |
| SCHEMBL16823709 | 0.81 | CHRNB2 (0.39) | CHRNB2CHRNA4EEDCHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL18185642 | 0.79 | CHRNB2 (0.38) | CHRNB2CHRNA4EEDCHRNB4CHRNA3 | |
| SCHEMBL17471302 | 0.79 | ALDH1A1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| CN-106029648-A | Substituted bipiperidinyl derivatives as adrenergic receptor alpha 2C antagonists | 拜耳制药股份公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| WO-2015091415-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318866-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNI3, TNNC1, FABP3 | CHRNB2 2949/4885CHRNA4 3230/4885EED 1556/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | CHRNB2 3755/4885CHRNA4 2812/4885EED 2384/4885 |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | IDH3B, IDH3A, EGLN3 | CHRNB2 1905/4885CHRNA4 2044/4885EED 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.